The customer observed falsely elevated alinity i afp results for one patient sample during a health screen.Results provided: (b)(6) 2022 afp initial result = 108.73 ng/ml, repeat result = 3.62 ng/ml additionally, the patient had the following test results: (b)(6) 2022 cea 1.88 ng/ml.(b)(6) 2022 ca19-9 6.10 u/ml.No impact to patient management was reported.
|
The complaint investigation for false elevated alinity i afp results included a review of data and information provided by the customer, search for similar complaints, ticket trending review, labeling review, device history record review, and field data review.Return testing was not completed as returns were not available.A review of tracking and trending did not identify any trends for the complaint issue.Labeling was reviewed and found to adequately address the issue.Data from customers worldwide was used to assess the performance of the alinity i afp assay.The median patient result for lot 39072fn00 is within established limits and comparable with other lots in the field, which indicates acceptable product performance.Device history record review on lot 39072fn00 did not show any potential non-conformances, deviations, or non-conformances associated with the complaint issue.Based on the investigation, no systemic issue or deficiency of the alinity i afp assay for lot number 39072fn00 was identified.All available patient information was included.Additional patient details are not available.
|